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Abstract
Background: 6XPPDU\ PHDVXUHV RI KHDOWK DUH HVVHQWLDO in PDNLQJ HVWLPDWHV RI KHDOWK VWDWXV WKDW DUH FRPSDUDEOH DFURVV WLPH DQG 
SODFH7KH\ FDQ EH XVHG IRU DVVHVVLQJ WKH SHUIRUPDQFH RI KHDOWK V\VWHPVLQIRUPLQJ HIIHFWLYH SROLF\ PDNLQJDQG PRQLWRULQJ WKH SURJUHVV 
RI QDWLRQV WRZDUG DFKLHYHPHQW RI VXVWDLQDEOH GHYHORSPHQW JRDOV7KH *OREDO %XUGHQ RI 'LVHDVHV,QMXULHVDQG 5LVN )DFWRUV 6WXG\  
*%' SURYLGHV GLVDELOLW\DGMXVWHG OLIH\HDUV'$/<VDQG KHDOWK\ OLIH H[SHFWDQF\+$/(DV PDLQ VXPPDU\ PHDVXUHV RI KHDOWK:H 
DVVHVVHG WKH WUHQGV RI KHDOWK VWDWXV in ,UDQ DQG  QHLJKERULQJ FRXQWULHV using WKHVH VXPPDU\ PHDVXUHV
Methods: :H XVHG WKH UHVXOWV RI *%'  to SUHVHQW WKH OHYHOV DQG WUHQGV RI '$/<VOLIH H[SHFWDQF\/(DQG +$/( in ,UDQ DQG its  
QHLJKERULQJ FRXQWULHV IURP  to )RU HDFK FRXQWU\ZH DVVHVVHG WKH UDWLR RI REVHUYHG OHYHOV RI '$/<V DQG +$/( to WKRVH H[SHFWHG 
EDVHG on VRFLRGHPRJUDSKLF LQGH[6',DQ LQGLFDWRU FRPSRVHG RI PHDVXUHV RI WRWDO IHUWLOLW\ UDWHLQFRPH SHU FDSLWDDQG DYHUDJH \HDUV 
RI VFKRROLQJ
Results: $OODJH QXPEHUV RI '$/<V UHDFKHG RYHU  PLOOLRQ \HDUV in ,UDQ in 7KH DOODJH QXPEHU RI '$/<V KDV UHPDLQHG VWDEOH 
GXULQJ WKH SDVW WZR GHFDGHV in ,UDQ GHVSLWH WKH GHFUHDVLQJ WUHQGV in DOODJH DQG DJHVWDQGDUGL]HG UDWHV7KH DOOFDXVH '$/< UDWHV 
GHFUHDVHG IURP  in  to  SHU  in 7KH VKDUH RI nonFRPPXQLFDEOH GLVHDVHV in '$/<V LQFUHDVHG in ,UDQIURP 
 to DQG DOO RI its QHLJKERUV EHWZHHQ  DQG WKH SDWWHUQ RI FKDQJH is VLPLODU in DOPRVW DOO  FRXQWULHV7KH '$/< UDWHV IRU 
1&'V DQG LQMXULHV in ,UDQ ZHUH KLJKHU WKDQ JOREDO UDWHV DQG WKH DYHUDJH UDWH in +LJK 0LGGOH 6', FRXQWULHVZKLOH WKRVH IRU FRPPXQLFDEOH
PDWHUQDOQHRQDWDODQG QXWULWLRQDO GLVRUGHUV ZHUH PXFK ORZHU in ,UDQ$PRQJ PHQFDUGLRYDVFXODU GLVHDVHV UDQNHG ¿UVW in DOO FRXQWULHV RI 
WKH UHJLRQ H[FHSW IRU %DKUDLQ$PRQJ ZRPHQWKH\ UDQNHG ¿UVW in  FRXQWULHV/LIH H[SHFWDQF\ DQG +$/( VKRZ D FRQVLVWHQW LQFUHDVH in DOO 
FRXQWULHV6WLOOWKHUH DUH GLVVLPLODULWLHV LQGLFDWLQJ D JHQHUDOO\ ORZ /( DQG +$/( in $IJKDQLVWDQ DQG 3DNLVWDQ DQG KLJK H[SHFWDQF\ in 4DWDU
.XZDLWDQG 6DXGL $UDELD,UDQ UDQNHG WK in WHUPV RI /( DW ELUWK DQG WK in WHUPV RI +$/( DW ELUWK in  ZKLFK LPSURYHG to WK IRU ERWK 
PHWULFV in 7XUNH\ DQG ,UDQ KDG WKH KLJKHVW LQFUHDVH in /( DQG +$/( IURP  to  ZKLOH WKH ORZHVW LQFUHDVH ZDV REVHUYHG in 
$UPHQLD3DNLVWDQ.XZDLW.D]DNKVWDQ5XVVLDDQG ,UDT
Conclusions: 7KH OHYHOV DQG WUHQGV in FDXVHV RI '$/<VOLIH H[SHFWDQF\DQG +$/( JHQHUDOO\ VKRZ VLPLODULWLHV EHWZHHQ WKH  FRXQWULHV
DOWKRXJK GLIIHUHQFHV H[LVW7KH GLIIHUHQFHV REVHUYHG EHWZHHQ FRXQWULHV FDQ EH DWWULEXWHG to D P\ULDG RI GHWHUPLQDQWVLQFOXGLQJ VRFLDO
FXOWXUDOHWKQLFUHOLJLRXVSROLWLFDOHFRQRPLFDQG HQYLURQPHQWDO IDFWRUV DV ZHOO DV WKH SHUIRUPDQFH RI WKH KHDOWK V\VWHP,QYHVWLJDWLQJ WKH 
GLIIHUHQFHV EHWZHHQ FRXQWULHV FDQ LQIRUP PRUH HIIHFWLYH KHDOWK SROLF\ DQG UHVRXUFH DOORFDWLRQ&RQFHUWHG HIIRUWV DW QDWLRQDO DQG UHJLRQDO 
OHYHOV DUH UHTXLUHG to WDFNOH WKH HPHUJLQJ EXUGHQ RI nonFRPPXQLFDEOH GLVHDVHV DQG LQMXULHV in ,UDQ DQG its QHLJKERUV
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Introduction
I ran is a large country in the Middle East with a unique geopolitical position in terms of its spread along a wide 
range of latitudes, diverse climate, and diversity of cultures 
and ethnicities.1,2 In 2015, the population of Iran reached 79 
million.3 This country has faced numerous social and economic 
challenges during the past four decades.1,2 A rapid demographic 
and epidemiologic transition is still ongoing in Iran.4 Urbanization 
has increased and the fertility rate has decreased following the 
1979 revolution.5 The overall socio-economic status has improved 
substantially.1,2,6 However, these changes have not been 
independent of overall trends in the Middle East, South Asia, and 
Central Asia. Iran has vast borders with 15 other countries that are 
located in various regions GH¿QHG by the World Bank.3 Iran has 
substantial trade with its neighbors as well as exchange of 
workforce and migrants, leading to exchange of culture and life 
style.5,6 Therefore, the socio-economic status and the general 
health status in Iran are likely to be LQÀXHQFHG by its neighbors. It 
is very important to estimate health status as well as its trends 
during the past two decade in Iran and to compare it with its 
neighbors. For this purpose, consistent summary measures are 
required to make comparisons across countries and time.   
With the replacement of millennium development goals 
(MDGs)7 with sustainable development goals (SDGs) in 2015,8 
summary measures of health have gained even more importance 
in identifying gaps, needs and priorities in health, and in guiding 
investments in health systems at national, regional, and global 
scales.9,10  SDGs encompass comprehensive targets that address 
non-communicable diseases (NCDs) and various factors that 
affect health.  A summary metric that can measure the progress of 
nations towards SDGs, especially those related to health and well-
being of people across the globe, can be very useful.11 Summary 
metrics can provide insight into the health status of nations and 
performance of the health systems. It is also important to measure 
what percentage of health loss is attributable to death and what 
percentage is lost due to disability. With aging of populations, a 
higher percentage of life is lost due to disability.12,13 The novel 
metrics devised in Global Burden of Diseases, Injuries, and Risk 
Factors Study (GBD) provide the possibility of disaggregating 
years of life lost (YLL) to premature mortality and years of lived 
with disability (YLD). The disability-adjusted life-year (DALY) 
is the sum of YLL and YLD that shows the life lost either to death 
as well as years lived at sub-optimal health with disability. DALY 
is the main measure that shows the gap in health. 
The second type of summary metrics measure health and 
life expectancy (LE). A single metric to measure healthy life 
expectancy (HALE) in populations was ¿UVW developed by 
Sullivan.14,15 In calculating HALE, years lived are weighted by a 
measure of functional health loss before death. A comprehensive 
range of causes of health loss are captured by HALE.12 
GBD is the most comprehensive study so far on summary metrics 
of health.16 To the best of our knowledge, there is hardly any other 
study that can cover the range of times and places captured in 
GBD and the methods used by it to measure uncertainties.
In this paper, we aim to present the levels and trends in DALYs, 
LE, and HALE in Iran and its 15 neighboring countries, based 
upon the estimated mortality and morbidity in previous steps 
of GBD 2015. The methods are generally similar to previous 
iterations of GBD.12,17,18 However, new data sources from 
new geographies have been included and methods have been 
improved. Additionally, the association of DALY and HALE 
with the development status of nations has been investigated.12 
The progress of nations is monitored and observed health status 
is compared with the expected status based on the position of 
countries within the spectrum of development. We have presented 
the levels as well as trends in DALYs, LE, and HALE for Iran and 
its 15 neighboring countries. Investigating the differences in health 
status and causes of death and disability between neighboring 
countries and countries with similar socio-economic, cultural, and 
political characteristics can inform more effective health policy 
and resource allocation in poorly performing countries.
Methods
The GBD is a systematic effort to measure health that can be 
comparable across time and place.16 The details of GBD 2015 
methodology for estimating DALYs, LE, and HALE have 
been described elsewhere.12,13,16–22 The results and data sources 
used for GBD 2015 are available through interactive tools on 
the website of the Institute of Health Metrics and Evaluation 
(IHME).23 Guidelines for Accurate and Transparent Health 
Estimates Reporting (GATHER) have been followed in all steps 
of analysis.24,25  
In short, GBD results cover 195 countries and territories in 21 
regions and 7 super-regions. There are four levels in the GBD 
cause hierarchy. Causes in each level are mutually exclusive and 
collectively exhaustive. The full list of GBD causes is available in 
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previous publications.13,19 
Mortality and non-fatal health loss in terms of YLL and YLD, 
respectively, have been estimated in GBD 2015. The details of 
their estimation are described in previous publications.12,13,19,26,27 
DALYs have been estimated by summing YLLs and YLDs by 
sex, age, country, and year for each cause. In GBD 2015, methods 
developed by Sullivan14,15 have been used to calculate HALE. 
To estimate 95% Uncertainty Intervals (UIs), 1000 draws from 
posterior distribution were taken for each estimation step. UIs 
capture uncertainty from multiple sources including sampling as 
well as model estimation and VSHFL¿FDWLRQ. The uncertainty in 
age-VSHFL¿F YLDs is assumed to be independent of age-VSHFL¿F 
YLLs used in DALYs and death rates in HALE.
In this paper, we report GBD 2015 results on DALYs by cause, 
LE, and HALE for Iran and all countries which have land or marine 
borders with Iran: Afghanistan, Bahrain, Iraq, Kuwait, Oman, 
Qatar, Saudi Arabia, Turkey, and United Arab Emirates in the 
region of Middle East and North Africa; Pakistan in South Asia; 
Armenia, Azerbaijan, Kazakhstan, and Turkmenistan in Central 
Asia; and Russia in Eastern Europe. Results have been estimated 
by sex, age (20 age groups), country, and year for each cause. 
In the GBD 2015, the association of the Socio-demographic 
Index (SDI) with DALY and HALE are investigated. SDI is the 
geometric mean of 3 indicators: 1) income per capita; 2) average 
years of schooling in people who are aged 15 years or more, and 
3) the total fertility rate. SDI values range between 0 and 1, with 
0 indicating the lowest income and schooling and highest fertility 
rate and 1 indicating the inverse. SDI values are calculated for 
each country for each year from 1980 to 2015. Expected LE and 
number of DALYs at each level of SDI have been estimated with 
the use of spline regressions. The observed life expectancy has 
been compared with expected life expectancy for all countries and 
years. The observed to expected DALYs for each country have 
been calculated.
Results
DALYs in Iran
All-age DALYs for all causes in Iran were 25.9 million years 
(95% UI: 23.3 – 28.5) in 1990 and 19.2 million years (95% 
UI: 16.2 – 22.3) in 2015. All-age DALYs decreased from 1990 
to 2000 (18.0 million years; 95% UI: 16.0 – 20.3), increased 
very slowly from 2000 to 2005, but remained relatively stable 
between 2005 and 2015 (Figure 1). The share of Group 1 causes 
Figure 1. $OODJH'$/<VDQGDJHVWDQGDUGL]HG'$/<UDWHVLQERWKVH[HVLQ,UDQIURPWR'$/<'LVDELOLW\$GMXVWHG/LIH<HDUV*URXS
GLVHDVHVFRPSULVHFRPPXQLFDEOHPDWHUQDOQHRQDWDODQGQXWULWLRQDOGLVHDVHV
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(B)
Figure 2./HDGLQJFDXVHVRIDJHVWDQGDUGL]HG'$/<UDWHVSHU LQDQG LQ ,UDQA) 0HQB):RPHQ*URXSGLVHDVHVDUH
SUHVHQWHGLQUHGQRQFRPPXQLFDEOHGLVHDVHVLQEOXHDQGLQMXULHVLQJUHHQ
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Figure 3.7KHGLVWULEXWLRQRIFDXVHVRI'$/<VDFURVVDJHJURXSVE\VH[LQLQ,UDQA)0HQB):RPHQ
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(communicable, maternal, neonatal, and nutritional diseases) 
from all-cause DALYs were 30% in 1990, 17% in 2000, and 
10% in 2015. The respective ¿JXUHV were 42%, 63%, and 74% 
for NCDs, and 28%, 20%, and 16% for injuries. These estimates 
show a decrease in the share of Group 1 causes and injuries along 
with a steep increase in the share of NCDs. DALY rates due to 
all causes showed a consistent decrease from 1990 to 2015 in 
Iran. All-cause DALY rates were 47,200 per 100,000 population 
in 1990, which decreased to 33,400 in 2005 and ultimately to 
28,400 in 2015. The trend for Group 1 causes decreased similarly, 
from 8,800 per 100,000 in 1990 to 3,900 in 2005 and 2,500 in 
2015. The respective ¿JXUHV for injuries were 11,600 per 100,000 
in 1990, which decreased to 5,500 in 2005 and ended in 3,900 
in 2015. The trend of DALY rates due to NCDs differed from 
their all-age numbers. The DALY rates of NCDs were 26,700 per 
100,000 in 1990, 24,100 in 2005, and 22,100 in 2015 (Figure 1). 
Figure 1 also demonstrates that the levels of DALY rates for all 
causes in Iran were lower than global estimates and almost similar 
to levels in High Middle SDI countries. The levels of DALY rates 
for Group 1 causes in Iran were much lower than estimates at 
global level and High Middle SDI countries, while the levels for 
NCDs and injuries were much higher.
Figure 2 demonstrates the top 20 causes of age-standardized 
DALY rates in 1990 and 2015 in Iran. Ten out of 20 leading causes 
in both years were NCDs. Cardiovascular diseases (CVDs) ranked 
¿UVW in both sexes in 1990 and 2015. Among men, the next leading 
causes of DALYs were transport injuries, mental disorders and 
substance use, and neoplasms. Among women, the leading causes 
of DALYs following CVDs were musculoskeletal disorders, 
other NCDs, and diabetes, urogenital, blood, and endocrine 
diseases. The highest rise in ranking pertained to mental disorders 
and substance use, neoplasms, musculoskeletal disorders, other 
NCDs, and diabetes, urogenital, blood, and endocrine diseases in 
both men and women, and transport injuries only in men. 
Figure 3 demonstrates the distribution of causes of DALYs 
across various age groups by sex in 2015 in Iran. The ¿JXUH shows 
that neonatal disorders were the main causes of DALYs in infants 
in both sexes. Among men in middle age groups, mental disorders 
and substance use, transport injuries, and unintentional injuries 
gained more importance, while among women in the same age 
groups, diabetes, urogenital, blood, and endocrine diseases, 
along with mental disorders and substance use, as well as 
musculoskeletal disorders were more important. Cardiovascular 
diseases were by far the most common causes of DALYs in old 
ages in both men and women in 2015. Neurological diseases also 
showed a rising trend among age groups older than 70 years.  
LE and HALE in Iran
Life expectancy at birth increased from 63.2 years in 1990 to 
69.6 years in 2005 and 71.9 years in 2015 in men. The respective 
estimates in women were 69.3 years in 1990, 74.6 years in 2005, 
and 78.0 in 2015. The observed life expectancy was similar to 
the expected value in 1990 in men. However, among women, 
the observed life expectancy was higher than expected in the 
same year. In 2003, the observed life expectancy fell below the 
expected value in both men and women due to an earthquake 
of high magnitude in Central Iran in that year. The observed 
value surpassed the expected value in 2004 in men and in 2010 
in women (Figure 4). In men, the HALE at birth increased from 
61.0 years in 2005 to 63.0 years in 2015. The respective estimates 
in women were 64.3 years in 2005 and 67.1 years in 2015. The 
increase in LE and HALE were almost similar in both men and 
women.
DALYs in Iran and its neighbors
Table 1 presents the age-standardized DALY rates per 100,000 
in Iran and its 15 neighboring countries in 1990, 2005, and 2015 
along with the SDI category to which they belong. Figure 5 also 
demonstrates the age-standardized DALY rates in 1990 and 2015 
and the percent change in rates from 1990 to 2015 in both sexes in 
the 16 countries. Afghanistan had the highest rates in 1990, 2005, 
and 2015. The second rank belonged to Pakistan in all years. The 
1990 2005 2015 SDI category
Afghanistan 96,500 (84,800 – 109,300) 88,700 (77,300 – 101,000) 82,000 (71,000 – 94,500) Low SDI
Armenia 36,900 (34,000 – 40,100) 32,600 (29,800 – 35,700) 27,400 (24,600 – 30,500) High–Middle SDI
Azerbaijan 46,900 (43,800 – 50,400) 39,700 (36,400 – 43,100) 30,800 (27,600 – 34,300) High–Middle SDI
Bahrain 33,900 (30,100 – 38,000) 26,700 (23,500 – 30,300) 22,400 (18,900 – 26,100) High–Middle SDI
Iran 47,200 (42,200 – 52,000) 33,400 (29,000 – 38,100) 28,400 (24,300 – 32,900) High–Middle SDI
Iraq 47,500 (42,100 – 53,200) 47,300 (41,500 – 54,600) 43,400 (36,900 – 50,300) Middle SDI
Kazakhstan 40,900 (38,000 – 44,300) 46,300 (43,200 – 49,600) 35,600 (32,100 – 39,300) High–Middle SDI
Kuwait 25,300 (22,200 – 28,900) 23,300 (20,500 – 26,500) 20,000 (17,000 – 23,300) High SDI
Oman 34,600 (29,400 – 40,200) 27,100 (23,700 – 30,600) 25,300 (21,500 – 29,100) High–Middle SDI
Pakistan 56,100 (51,900 – 60,500) 55,500 (51,100 – 60,400) 46,700 (42,100 – 52,100) Low–Middle SDI
Qatar 29,500 (26,100 – 33,000) 26,300 (22,800 – 29,900) 21,500 (18,100 – 25,500) High–Middle SDI
Russia 38,400 (35,300 – 41,900) 47,000 (44,000 – 50,000) 34,600 (31,500 – 38,000) High SDI
Saudi Arabia 31,200 (27,900 – 35,300) 24,000 (21,200 – 27,200) 21,500 (18,500 – 24,700) High–Middle SDI
Turkey 42,600 (39,200 – 46,300) 27,200 (24,200 – 30,500) 22,700 (19,600 – 26,100) High–Middle SDI
Turkmenistan 49,800 (46,300 – 53,800) 44,900 (41,200 – 49,000) 36,100 (32,800 – 39,700) High–Middle SDI
United Arab Emirates 36,000 (30,700 – 41,600) 27,700 (24,300 – 31,300) 26,800 (22,500 – 31,900) High SDI
Figures in parentheses show the 95% uncertainty intervals. DALY: disability–adjusted life years. SDI: socio–demographic index.
Table 1.$JHVWDQGDUGL]HG'$/<UDWHVSHULQDQGIRUDOOFDXVHVLQERWKVH[HVLQFRXQWULHVDQGWKH6',FDWHJRU\WR
ZKLFKHDFKFRXQWU\EHORQJV
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(A) (B)
(C)
Figure 4./LIH([SHFWDQF\DWELUWKLQ,UDQIURPWR7KHH[SHFWHGOLIHH[SHFWDQF\LVFDOFXODWHGEDVHGRQWKH6RFLR'HPRJUDSKLF,QGH[
6',IRU+LJK0LGGOH,QFRPHFRXQWULHVWKHFDWHJRU\WRZKLFK,UDQEHORQJV7KHVKDUSGHFUHDVHLQOLIHH[SHFWDQF\IRUERWKZRPHQDQGPHQLQ
LVGXHWRWKHHDUWKTXDNHLQFHQWUDO,UDQLQWKDW\HDU
Figure 5.7KHDJH±VWDQGDUGL]HGUDWHRI'$/<VSHUIRUDOOFDXVHVLQDQGDQGWKHSHUFHQWFKDQJHLQUDWHVIURPWRLQERWK
VH[HVLQFRXQWULHVA)'$/<UDWHVSHULQB)'$/<UDWHVSHULQC)3HUFHQWFKDQJHLQ'$/<UDWHVIURPWR
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lowest rates belonged to Kuwait in all 3 years. Iran ranked 12th 
in 1990, which improved to 9th in 2005 and 2015. The steepest 
decrease in DALY rates occurred in Turkey and Iran, while there 
was not a substantial decrease in Iraq and Russia.
Figure 6 demonstrates the distribution of major causes of 
DALYs in the 16 countries in 2015. A large portion of DALY 
rates in Afghanistan, Iraq, and Russia were caused by injuries 
in both sexes. The share of Group 1 diseases was still quite 
high in Afghanistan and Pakistan (34% and 46% respectively). 
Cardiovascular diseases contributed to a large share of DALY 
rates in Russia and Kazakhstan. Afghanistan suffered from the 
triple burden of communicable and non-communicable diseases 
as well as injuries. In Iran, cardiovascular diseases had the largest 
share of DALY causes in both sexes. 
Figure 7 demonstrates the ranking of top 20 causes of all age 
DALY rates in the 16 countries. In men, cardiovascular diseases 
had the highest rank in 15 countries, but ranked second in Bahrain. 
Transport injuries ranked second in Iran. War and disaster ranked 
second in Afghanistan and Iraq. Mental disorders and substance 
abuse ranked 3rd or 4th in Bahrain, Iran, Kazakhstan, Kuwait, 
(A)
(B)
Figure 6. 'LVWULEXWLRQRIFDXVHVRI'$/<UDWHVDFURVVFRXQWULHVLQA)0HQ B):RPHQ
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Figure 7.5DQNVRIWRSFDXVHVRIDJHVWDQGDUGL]HG'$/<UDWHSHULQFRXQWULHVA)0HQB):RPHQ
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Qatar, Russia, Saudi Arabia, and the United Arab Emirates (UAE). 
Neonatal disorders still ranked second in Pakistan. Neoplasms 
held the second rank in Armenia, Azerbaijan, Kazakhstan, Russia, 
and Turkey. Diabetes, urogenital, blood, and endocrine diseases, 
unintentional injuries, musculoskeletal, neonatal, and neurological 
disorders, chronic respiratory diseases, infectious diseases, as well 
as self-harm and violence occupied the middle ranks. The lowest 
ranks belonged to nutritional GH¿FLHQFLHV, digestive diseases and 
cirrhosis, HIV/AIDS, tuberculosis, war and disaster, neglected 
tropical diseases (NTDs), and malaria.
The pattern was almost similar in women. Cardiovascular 
diseases ranked ¿UVW in 13 countries, second in Bahrain, and 
third in Qatar and Turkey. Diarrhea, lower respiratory infections 
and other infections ranked second in Afghanistan and third in 
Pakistan and Turkmenistan. The pattern of middle ranked causes 
was similar to men, the main difference being the generally lower 
rankings of transport injuries, self-harm and violence, as well as 
war and disasters.
Table 2 demonstrates the ratio of observed to expected number 
of DALYs for top 10 causes in each country, based on the SDI 
category to which each country belongs. Generally, ischemic 
heart disease (IHD), diabetes, neonatal encephalopathy, and road 
injuries were among the top causes of DALYs with observed to 
expected ratio of over 1.00. War was the top cause in Afghanistan 
and Iraq, with an observed to expected ratio of over 1,000 in both 
countries. The ratios for back and neck pain and depression were 
generally low, while the patterns for other causes showed more 
variability.
(A) (B)
(C)
Figure 8./LIHH[SHFWDQF\/(DWELUWKLQFRXQWULHVLQDQGDQGWKHLUSHUFHQWFKDQJHGXULQJWKLVWLPHSHULRGA)/(DWELUWKLQB) 
/(DWELUWKLQC)3HUFHQWFKDQJHLQ/(IURPWR
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LE and HALE in Iran and its neighbors
Figures 8 and 9 demonstrate the life expectancy (LE) and 
healthy life expectancy (HALE) at birth in the 16 countries in 
1990 and 2015 and their percent change during this time period. 
Qatar, Kuwait, and Saudi Arabia had the largest LE and HALE 
at birth both in 1990 and 2015. Pakistan and Afghanistan had the 
lowest LE and HALE at birth at these two time points. Iran ranked 
11th in terms of LE at birth and 12th in terms of HALE at birth 
in 1990 which improved to 9th in both metrics in 2015. Between 
1990 and 2015, Turkey had the highest change in terms of both LE 
and HALE at birth. As a result, Turkey’s rank improved from 9th 
in terms of LE and 10th in terms of HALE to 4th for both metrics in 
2015. After Turkey, Iran had the second steepest increase in LE and 
HALE at birth. LE at birth increased from 66.0 years in 1990 to 
74.6 years in 2015 in Iran. Respective ¿JXUHV for HALE were 57.0 
years in 1990 and 64.9 years in 2015. Azerbaijan, Afghanistan, 
Bahrain, and Turkmenistan were the next countries with the 
highest increase in their LE and HALE at birth. At the other end 
of the spectrum, Armenia, Pakistan, Kuwait, Kazakhstan, Russia, 
and Iraq had the least increase in their LE and HALE at birth.
LE at birth in 2005 and 2015 and those at age 65 years in 2015 
for all 16 countries are demonstrated by sex in Table 3. The results 
mirror those presented in Figures 8 and 9. At almost all time points, 
LE and HALE were considerably higher in women compared to 
men; exceptions were LE and HALE at birth in 2005 and LE and 
HALE at age 65 years in 2015 in Afghanistan. The greatest gap 
between LE and HALE at birth between men and women was 
observed in Russia in 2005, where the LE and HALE at birth in 
women were 13.5 and 10.2 years more than those in men. The 
next greatest gaps between men and women were observed in 
(A) (B)
(C)
Figure 9. +HDOWK\OLIHH[SHFWDQF\+$/(DWELUWKLQFRXQWULHVLQDQGDQGWKHLUSHUFHQWFKDQJHGXULQJWKLVWLPHSHULRGA)+$/(DWELUWK
LQB)+$/(DWELUWKLQC)3HUFHQWFKDQJHLQ+$/(IURPWR
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Kazakhstan, Turkmenistan, and Armenia. The smallest gaps 
were observed in Afghanistan and Pakistan. The pattern of gaps 
between LE and HALE at birth in 2015 was almost similar to 
2005, with greatest gaps in Russia, Kazakhstan, Turkmenistan, 
and Armenia, and the smallest gaps in Afghanistan and Pakistan. 
As for LE and HALE at age 65 years in 2015, the greatest gaps 
were observed in Russia, Turkey, Kazakhstan, Armenia, and 
Turkmenistan. The smallest gaps were observed in Afghanistan, 
Kuwait, and Pakistan. In Iran, the gap between women and men in 
LE and HALE at birth increased from 4.9 and 3.3 years in 2005, 
to 6.1 and 4.1 years in 2015. The gap in LE and HALE at age 65 
years were 2.8 and 1.9 years, respectively, in 2015.
Discussion
The GBD 2015 provides several summary measures that help 
assess the overall performance of the health systems in the past 
decades. Many measures have improved in Iran; however, the 
pattern of disease burden shows VLJQL¿FDQW changes. The results of 
GBD 2015 showed that all-age number of DALYs have remained 
stable during the last decade in Iran, despite decreasing rates. 
The share of NCDs caused DALYs has increased throughout the 
evident epidemiologic transition in Iran. The decreases in rates 
of communicable, maternal, neonatal, and nutritional diseases 
as well as injuries were much steeper than the decrease in rate 
of NCDs. Ten out of 20 leading causes of DALYs were among 
NCDs, which is in line with reports of previous iterations of 
the GBD28,29 and previous burden of disease studies in Iran.30,31 
CVDs were the leading cause of DALYs and there was substantial 
increase in DALYs due to musculoskeletal disorders, diabetes, 
neoplasms, and mental disorders and substance use. Transport 
injuries ranked second in men in Iran. The high rank of transport 
injuries in men in Iran is alarming and needs VSHFL¿F attention by 
health authorities as well as other organizations out of the health 
sector, such as the transportation industry, that should be involved 
in adopting effective strategies to tackle this challenge in Iran.32,33
1 2 3 4 5 6 7 8 9 10
Afghanistan War(1033.96)
LRI
(0.70)
IHD
(4.31)
Congenital
(1.56)
Stroke
(2.15)
NN Preterm
(0.77)
Road
(2.38)
Other Unint
(9.71)
Diarrhea
(0.24)
Violence
(4.00)
Armenia IHD(1.52)
Stroke
(0.87)
Diabetes
(1.71)
Back & Neck
(1.00)
Sense
(1.03)
Lung C
(1.29)
Depression
(1.01)
Congenital
(1.21)
COPD
(0.93)
Road
(0.64)
Azerbaijan IHD(2.31)
LRI
(3.36)
Stroke
(1.25)
Back & Neck
(0.98)
NN Enceph
(7.12)
Diabetes
(1.53)
NN Preterm
(2.17)
Sense
(1.08)
Depression
(1.02)
Congenital
(1.07)
Bahrain Diabetes(3.31)
Back & Neck
(0.95)
IHD
(0.83)
Depression
(1.11)
Skin
(1.04)
Road
(0.57)
Other MSK
(1.92)
Sense
(1.02)
Congenital
(0.90)
Migraine
(1.07)
Iran IHD(1.24)
Road
(1.69)
Back & Neck
(1.03)
Stroke
(0.76)
Diabetes
(1.20)
Congenital
(1.02)
Depression
(1.05)
Sense
(0.94)
Other Cardio
(3.76)
Drugs
(4.09)
Iraq War(1932.51)
IHD
(1.83)
Congenital
(1.22)
NN Preterm
(0.70)
Diabetes
(1.78)
Stroke
(1.14)
NN Sepsis
(2.44)
Road
(0.68)
Back & Neck
(1.08)
LRI
(0.40)
Kazakhstan IHD(2.77)
Stroke
(2.18)
Back & Neck
(1.04)
Self–harm
(2.14)
Road
(1.46)
NN Preterm
(2.88)
Iron
(2.40)
Congenital
(1.21)
LRI
(1.76)
Sense
(1.10)
Kuwait IHD(1.94)
Back & Neck
(0.88)
Depression
(1.18)
Congenital
(1.62)
Road
(1.32)
Diabetes
(2.18)
Migraine
(1.06)
Skin
(0.88)
Sense
(1.09)
Iron
(1.18)
Oman Road(1.60)
Other Cardio
(9.17)
Back & Neck
(0.95)
Diabetes
(2.26)
IHD
(0.79)
Depression
(1.07)
Congenital
(0.71)
Sense
(1.01)
Migraine
(1.10)
Skin
(0.86)
Pakistan NN Enceph(2.86)
IHD
(1.73)
NN Preterm
(0.85)
LRI
(0.61)
Diarrhea
(0.88)
Stroke
(0.86)
Iron
(1.02)
TB
(1.32)
Diabetes
(1.31)
Other 
Unint
(4.33)
Qatar Road(1.48)
Back & Neck
(0.94)
Diabetes
(2.92)
Depression
(1.15)
IHD
(0.67)
Migraine
(1.12)
Skin
(0.94)
Congenital
(1.13)
Sense
(0.96)
Anxiety
(1.05)
Russia IHD(3.28)
Stroke
(2.49)
Back & neck
(1.20)
Self–harm
(2.00)
Sense
(1.30)
CMP
(9.71)
Road
(2.09)
Alcohol
(10.72)
Drugs
(5.90)
Depression
(1.14)
Saudi Arabia Back & Neck(0.99)
IHD
(0.84)
Road
(1.23)
Congenital
(1.29)
Depression
(1.11)
Skin
(0.95)
Migraine
(1.27)
Diabetes
(1.15)
Sense
(1.01)
NN Preterm
(1.01)
Turkey Back & Neck(1.13)
IHD
(0.53)
Diabetes
(0.97)
Congenital
(0.97)
Sense
(0.85)
Stroke
(0.40)
Depression
(0.92)
NN Preterm
(0.82)
Lung C
(1.18)
Road
(0.51)
Turkmenistan IHD(2.96)
LRI
(6.42)
Stroke
(2.21)
Congenital
(1.76)
Back & Neck
(0.94)
NN Preterm
(2.59)
NN Enceph
(5.53)
Diabetes
(1.56)
Depression
(1.00)
Sense
(1.06)
United Arab 
Emirates
IHD
(2.63)
Road
(3.09)
Back & Neck
(0.99)
Diabetes
(3.48)
Stroke
(2.11)
Depression
(1.18)
Other MSK
(1.90)
Migraine
(1.14)
Skin
(0.93)
Drugs
(1.93)
The ratio of observed DALYs to DALYs expected based on SDI is provided in brackets for each cause and cells are color coded by ratio ranges (calculated to 
place a roughly equal number of cells into each bin). Shades of velvet, blue and green represent much lower observed DALYs than expected levels based on 
SDI, whereas yellow, orange, and red show observed DALYs that exceed expected levels. 
IHD: ischemic heart disease; Back & neck: low back and neck pain; Diabetes: diabetes mellitus; Stroke: Cerebrovascular disease; Lung C: lung, bronchus, 
and trachea cancers; Sense: sense organ diseases; Depression: depressive disorders; Oth MSK: other musculoskeletal disorders; COPD: chronic obstructive 
pulmonary disease; NN Preterm: neonatal preterm birth complications; Diarrhea: diarrheal diseases; Skin: skin and subcutaneous diseases; NN Enceph: 
neonatal encephalopathy due to birth asphyxia and trauma; Drugs: drug use disorders; Congenital: congenital anomalies; Anxiety: anxiety disorders; Iron: 
LURQ±GH¿FLHQF\DQHPLD/5,ORZHUUHVSLUDWRU\LQIHFWLRQV&03FDUGLRP\RSDWK\DQGP\RFDUGLWLV2WKHU&DUGLRRWKHUFDUGLRYDVFXODUDQGFLUFXODWRU\
diseases; Alcohol: alcohol use disorders; Violence: interpersonal violence; TB: tuberculosis; War: collective violence and legal intervention; Other Unint: 
other unintentional injuries; Road: road injuries. 
GBD: Global Burden of Disease. SDI: Socio–demographic Index. DALYs: disability–adjusted life–years. 
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The distribution of causes across age groups also showed 
that neonatal disorders are still the main causes of burden in 
infants, indicating that the efforts of the health system have not 
been adequate for preventing this group of diseases. Middle-
aged groups are mainly affected by mental and substance use 
disorders and injuries while older age groups suffer from CVDs. 
The burden of diabetes and musculoskeletal disorders is higher 
on women than men. The observed rate of DALYs caused by 
IHD and other cardiovascular diseases, road injuries, substance 
use, and diabetes were VLJQL¿FDQWO\ higher than expected levels, 
while those for stroke and sense organ diseases were lower. These 
¿QGLQJV illustrate the importance of developing policies that are 
tailored to VSHFL¿F needs and priorities of every nation based on 
the distribution of main causes of burden across sex and age sub-
groups.
Life expectancy and HALE increased steadily in Iran between 
1990 and 2015. The observed levels were higher than expected 
levels at most time points from 1990 to 2015. Women lived 
longer than men at all time points. The VLJQL¿FDQW increase in 
life expectancy and HALE are good proxies for improvement of 
overall health status and living standards in Iran. The gap in LE 
and HALE between men and women has remained constant in Iran 
while in many countries, men have shown larger improvements in 
their LE and HALE in recent years. 
From 1990 to 2015, among all 16 countries, DALY rates were 
the highest in Afghanistan and the number of DALYs were 
the highest in Pakistan and Russia, mostly due to their larger 
population size. The least rates were observed in Kuwait, while 
the steepest decrease occurred in Turkey and Iran. Overall, it 
seems that the performance of the health system has substantially 
improved in Turkey and Iran among other countries, while there 
was almost no improvement in Iraq and Russia. The rather slow 
improvement in Iraq can be attributable to the long-term political 
instability, while there is no such clear MXVWL¿FDWLRQ for Russia. 
Afghanistan and Pakistan suffer from the triple burden of NCDs 
and Group 1 diseases, as well as injuries. Apart from Afghanistan, 
Iraq, and Pakistan, the overall pattern of causes of DALYs were 
almost similar across countries, with CVDs occupying the highest 
ranks followed by neoplasms, mental disorders and substance use, 
and diabetes and endocrine diseases. Exceptions were the high 
rank of transport injuries in Iran and musculoskeletal disorders in 
women in most high-income countries of the region.
The observed to expected ratio was higher than 1.00 for 
most causes in Afghanistan, Iraq, Kazakhstan, Russia, and 
Turkmenistan, while the ratio was below 1.00 for most causes 
in Saudi Arabia and Turkey. LE and HALE were the lowest in 
Afghanistan and Pakistan, the highest in Qatar, Kuwait, and Saudi 
Arabia, and substantially improved in Iran and Turkey. In order 
to improve further, policies should be developed and VSHFL¿FDOO\ 
tailored for countries for causes whose observed DALYs are 
higher than expected values.
Overall, the health status has substantially improved in almost all 
16 countries since 1990 and particularly during the past decade. 
The change in burden due to causes from Group 1 diseases to 
NCDs is also consistent across countries. Life expectancy has 
increased in all countries. The longer life expectancy means better 
health status, but it also means that more years are lived with 
functional health loss.  
Despite similarities, there were also great differences in major 
causes of DALYs between Iran and its neighboring countries. 
The observed differences between countries can be attributed 
to a myriad of determinants, including social, cultural, ethnic, 
religious, political, economic, and environmental factors as 
well as the performance of the health systems.34 Equal access to 
health care is a major determinant of health system performance. 
Investigating the differences in health status as well as causes of 
death and disability between neighboring countries and countries 
with similar socio-economic, cultural, and political characteristics 
can inform more effective policy making and resource allocation 
in countries with inadequate performance. Indeed, a great portion 
of the variability between these 16 countries is attributable to 
political instabilities.
GBD results showed the rising share of NCDs in DALYs in 
almost all countries across the world. In 2015, the United Nations 
called for a one-third reduction in NCD premature mortality 
by 2030.8 Following the call, the Iranian Non-Communicable 
Disease Committee (INCDC) was formed in the Ministry of 
Health in Iran and is directly headed by the Minister of Health.35 
Controlling NCDs requires a coordinated health care system 
with effective and transparent funding.36 Several challenges 
should be overcome, including high level of out-of-pocket 
payment, LQVXI¿FLHQW health insurance plans, poor inter-sectoral 
collaborations, poor partnership between public and private 
sectors, and low general awareness about NCDs and injuries. Part 
of these challenges will be overcome upon implementation of a 
universal health care system. The extensive primary health care 
system in Iran is a major point of strength as it provides an ideal 
setting for integration of comprehensive and equitable health care 
services into existing care. The actual integration of these services 
into the health care system requires the commitment of policy 
makers in the highest levels of the health sector and collaboration 
of non-health sectors that are somehow involved in this concerted 
effort at the national level. 
Limitations
While GBD has many strengths, the methodology has several 
limitations, as well. First, the limitations of all previous analytical 
steps in the GBD are inherent in calculating DALYs and 
HALE. These steps include calculation of all-cause and cause-
VSHFL¿F mortality, prevalence, incidence, disability weight, and 
comorbidities. Second, limitations in availability and quality 
of data are among major contributors to uncertainties in GBD 
estimates for data-poor times and places. Third, although the 
correlation of DALYs and HALE with SDI was often observed 
to be strong, the relationship cannot be considered as causal. In 
cases when the components of SDI were used as covariates in 
models, the association of health indicators with SDI could be 
considered as a confounder. In future iterations of GBD, other 
components of development (such as inequality) may be added 
to SDI. Fourth, the uncertainty of YLDs has been assumed to be 
independent of the uncertainty in YLLs and life expectancy. Fifth, 
due to time lag in data capture, all aspects of health loss due recent 
mass migration in Syria and Libya have not been covered in our 
estimates. Finally, as expected estimates of burden are only based 
on average SDI in each level, the observed to expected ratios for 
endemic diseases will be high in endemic countries and low in 
non-endemic countries.      
In conclusion, in this paper, we presented the main drivers 
of DALYs in Iran and its neighboring countries as well as the 
trends in life expectancy and HALE as main summary measures 
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for monitoring progress of nations towards SDGs. We showed 
the change in the pattern of diseases in line with epidemiologic 
transition in Iran and the relatively substantial improvement in 
health status in Iran compared with its neighbors. Universal and 
comprehensive action plans are required to tackle the emerging 
epidemic of NCDs and injuries in Iran. Lessons can be learned 
from best-performing countries with socio-economic status 
similar to Iran.
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